Low Prevalence of Adverse Outcomes in an 18-Month Follow-Up of Individuals With Chronic Pain Recently Certified for Medical Cannabis
BACKGROUND: Given the scarce data on adverse outcomes in people who use medical cannabis, the objective of this study was to assess the prevalence of adverse outcomes, including cannabis use disorder (CUD), opioid use disorder (OUD), hazardous alcohol use, cannabis diversion, cannabis-related injuries, and emergency room visits in individuals newly certified for medical cannabis for chronic pain in New York. METHODS: In an 18-month longitudinal cohort study, data were collected from 223 adults (mean age = 56.3 years, 54.3% female). At baseline and every 3 months, we assessed study outcomes using structured DSM-5 diagnostic interviews, standardized questionnaires, and study-specific questions. Medical and unregulated cannabis use were self-reported separately every 2 weeks via web surveys. FINDINGS: Over 18 months, 4.9% of participants met the DSM-5 criteria for CUD at 1 or more study visits, 0.9% for OUD, 6.7% for hazardous alcohol use, 4.0% for cannabis diversion, and 1.8% for cannabis-related injuries. The mean frequency of medical and unregulated cannabis use per 2-week period was 9.6 and 5.3 days, respectively, for those with CUD and 6.4 and 2.7 days, respectively, for those without CUD. No consistent patterns emerged for other adverse outcomes. CONCLUSIONS: In this cohort of adults with chronic pain newly certified for medical cannabis, adverse outcomes were infrequent during the 18-month follow-up, despite participants reporting regular use throughout the study. However, these findings should be interpreted with caution, as larger or longer term studies may detect risks not captured in this study. Continued patient education and monitoring remain important, and more research is needed to understand the long-term safety of medical cannabis use, particularly as policies continue to evolve.
Authors
- Yuval Zolotov (ORCID: https://orcid.org/0000-0002-5391-7379)
- Chinazo O. Cunningham (ORCID: https://orcid.org/0000-0002-7930-313X)
- Joanna L. Starrels (ORCID: https://orcid.org/0000-0002-1865-1966)
- Deepika E. Slawek (ORCID: https://orcid.org/0000-0001-8403-8433)
- Julia Hope Arnsten (ORCID: https://orcid.org/0000-0002-7741-1567)
- Jonathan Ross (ORCID: https://orcid.org/0000-0001-6126-3048)
- FRANCES RUDNICK LEVIN (ORCID: https://orcid.org/0000-0003-4209-1329)
- Nancy Sohler (ORCID: https://orcid.org/0000-0003-3147-1297)
- Stephen Dahmer
- Chenshu Zhang
Institutions
- Albert Einstein College of Medicine (US)
- Montefiore Medical Center (US)
- University of Arizona (US)
- City University of New York (US)
- Ariel University (IL)
- Columbia University (US)
Publication Details
- Journal
- Substance Use & Addiction Journal
- Published
- 2026-11-20
- DOI
- https://doi.org/10.1177/29767342261496711
- Primary Topic
- Cannabis and Cannabinoid Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute of Mental Health
- National Institute on Drug Abuse